$ALMU

Klamkin Jonathan sold $1.3M of ALMU (indirect holdings)

Klamkin Jonathan (Chief Executive Officer) sold 100,000 indirectly-held shares of Aeluma, Inc. (ALMU) at $13.35 ($1.34M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Klamkin Jonathan
Published Sep 23, 2026, 11:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMU
Bearish
medium confidence
Mentioned
$ALMU
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMUBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, potentially affecting investor perception of confidence.

02

Market read

New insider sell adds modest negative sentiment for ALMU; limited broader market impact.

03

What to watch

The 10b5-1 plan pre-arranged sale may have been scheduled long before any material news.

Relevance 5/10Novelty 7/10Timing: filing date 2026-09-23

Background

Form 4 filings disclose insider transactions; a CEO sale often draws investor attention.

Company-level read

Ticker impact

$ALMUBearishMedium confidence
Context

CEO Jonathan Klamkin sold 100,000 shares for $1.33M via a 10b5-1 plan, reducing his stake to 1,226,995 shares.

Expected impact

Possible modest downward pressure over the next few days.

Evidence & confidence

Large insider sale by the CEO, disclosed via Form 4, often leads to negative market reaction, especially when no accompanying positive news.

Market effects

May raise concerns for the biotech/health sector if similar insider activity is observed.

Limited to US markets where ALMU trades.

Low, as the company is small-cap with limited global exposure.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Aeluma, Inc.

    Biotech firm listed on NASDAQ under ticker ALMU.

  • Jonathan Klamkin

    Chief Executive Officer of Aeluma, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMUMed

Aeluma (ALMU) Q4 2026 Earnings Call Transcript

Aeluma (ALMU) reported Q4 2026 revenue of $582,000 and a GAAP net loss of $4 million, or $0.22 per share. Full-year revenue was $4.5 million, down from $4.7 million in 2025. The company is shifting focus to the AI datacom market, investing in manufacturing and hiring, with $56 million in cash reserves. It expects $2.3 million in government revenue for 2027 and is pursuing additional contracts and partnerships.

High

Why is Aeluma stock surging today?

Aeluma stock rose 7.0% in pre-market trading after announcing a partnership with Sumitomo Chemical Advanced Technologies to develop and manufacture photonics wafers for AI datacom. The company is set to report Q4 and full-year 2026 earnings on September 16. The sole analyst's price target of $30.50 suggests significant upside from current levels.

$ALMUMed

The Speed of Light: 5 Stocks Powering AI’s Optical Future

MarketBeat highlights NVIDIA’s broader photonics investment and says the global photonics market is about $1.25T, growing mid-single digits through the next decade, with silicon photonics rising ~30% annually. It profiles Aeluma (NASDAQ: ALMU), citing quantum-dot lasers and a manufacturing method that grows optical-quality substrate on silicon. The article notes Aeluma is pre-revenue, seeks data-center/defense partnerships for design wins and prototype certifications, and targets production and

$ALMUMedAI 8/10

Aeluma Sees Accelerated Timeline for Quantum Commercialization

Aeluma (NASDAQ: ALMU) said the U.S. Department of Commerce announced proposed CHIPS Act incentives of more than $2 billion for nine companies to accelerate quantum computing, shifting from R&D to manufacturing. Aeluma supported one company that signed a letter of intent, with involvement contingent on a subcontract. Aeluma cited its scalable wafer platform and recent U.S. contracts for quantum materials and lasers.